HomeStructural heart diseaseValvular Aortic Valve

Valvular Aortic Valve

HYDRA CE | New Models for TAVR Development

The Hydra CE has shown favorable one year efficacy for the new transcatheter aortic valve model, with...

Minimizing One of Our Major Procedures to a Minimum

In some cases, full atrioventricular (AV) block occurs beyond two days after transcatheter aortic valve replacement (TAVR)....

The FDA Approves Sapien 3 with Alterra in Pulmonary Position

The US Food and Drug Administration (FDA) has cleared the SAPIEN 3 valve with the Alterra adaptive pre-stent...

The Most Relevant of 2021 In Structural Heart Disease

This last year, new data in structural heart disease gave way to changes in practices and new...

PRAGUE-17: Appendage Closure vs. Direct Anticoagulant Agents

After four years of follow-up, the PRAGUE-17 study showed that appendage closure is non-inferior to direct anticoagulant...

CHOICE-CLOSURE | Which Closure Device for TAVR is Better?

In patients who undergo transcatheter aortic valve replacement (TAVR) through transfemoral access, a closure device based on...

Prosthesis-Annular Size Ratio and Its Impact on Leaks

In low-risk patients, there was a very low incidence of greater than moderate leak, including in patients...

Ten Commandments for 2021 Guidelines on Valvular Heart Disease

Since the latest version to the Valvular Heart Disease Guidelines from the European Society of Cardiology, plenty...